IL18BP and renal cell carcinoma: Our human transcriptomic, qIF, and ELISA findings in RCC suggest that the IL-18 pathway may be poised for reactivation in RCC with an agent like DR-18 that can bypass the inhibitory protein IL-18BP, particularly in ICI-nonresponding patients.